Australia's largest health company CSL should boost its R&D spending or risk losing market share in the vaccine business to the technology behind one of the world’s leading COVID-19 vaccine candidates, according to Platinum Asset Management's Bianca Ogden.

The portfolio manager leads Platinum’s international health care fund and boasts a science and industry background that spans a doctoral degree in virology and time in drug research with healthcare giant Johnson & Johnson.